Source: PLoS One
Area: News
The authors of this paper carried out a systematic review based on randomised controlled clinical trials (RCTs) to assess whether unlicensed therapy with bevacizumab is as safe as licensed therapy with ranibizumab for the treatment of age related macular degeneration (AMD), and whether bevacizumab can be justifiably offered to patients with AMD as a medication with no additional risk. The authors also evaluated whether adverse effects (AEs) are dose-related.
Data for the review were sourced from various databases (Embase, Medline, and Cochrane Library) and (Read more...)